Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
May 17, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results
May 15, 2017 07:30 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - May 15, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
May 08, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - May 8, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
April 27, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Apr 27, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
April 20, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Apr 20, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous...
Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
April 18, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Apr 18, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
Aldeyra Therapeutics Reports Full Year 2016 Financial Results
March 30, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Mar 30, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
March 22, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
February 28, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Feb 28, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome
February 22, 2017 08:00 ET
|
Aldeyra Therapeutics
LEXINGTON, MA--(Marketwired - Feb 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...